Heart and Blood Diseases

All Conditions

Embolism

Thromboembolism

Venous Thromboembolism

Thrombosis

Embolism and Thrombosis

Vascular Diseases

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Micronutrients

Coagulants

Anti-Infective Agents

Vitamins

Amino Acids

Heparin

Edoxaban

Rivaroxaban

Apixaban

Dabigatran

Vitamin K

Calcium heparin

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Factor Xa Inhibitors

Antithrombins

Antithrombin III

Protease Inhibitors

Serine Proteinase Inhibitors

HIV Protease Inhibitors

Enzyme Inhibitors

Menadione

Menaquinone

Naphthoquinone

Phylloquinone

Serine

LMWH

Pfizer CT.gov Call Center

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Anticoagulation in Patients With Venous Thromboembolism and Cancer

VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe)

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

The follow-up period during which outcome events of interest will be identified will run from the day after the index date until the end of the data collection or death, whichever occurs first. As data are updated at different times and frequencies in the different study countries, the date of the end of data collection will be determined after the relevant permissions have been acquired from the respective authorities.

Pfizer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Anticoagulation in Patients With Venous Thromboembolism and Cancer	NCT04618913	Neoplasms Embolism	Apixaban Rivaroxaban Edoxaban Dabigatran VKA LMWH	18 Years -	Pfizer
Anticoagulation in Patients With Venous Thromboembolism and Cancer	NCT04618913	Neoplasms Embolism	Apixaban Rivaroxaban Edoxaban Dabigatran VKA LMWH	18 Years -	Pfizer

Spots Global Cancer Trial Database for eliquis

Every month we try and update this database with for eliquis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for eliquis

Every month we try and update this database with for eliquis cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for eliquis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.